T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly

作者：Iulia Potorac, Patrick Pétrossians, Adrian Daly, Orsalia Alexopoulou, Sophie Borot, Mona Sahnoun-Fathallah, Frédéric Castinetti, France Devuyst, Marie‐Lise Jaffrain‐Rea, Claire Briet, Florina Luca, Marion Lapoirie, Flavius Zoicas, Isabelle Simoneau, Alpha Mamadou Diallo, Ammar Ali Muhammad, Fahrettin Keleştimur, Elena Nazzari, Rogelio García Centeno, Susan M. Webb, Marie Laure Nunes, Václav Hána, Veronique Pascal-Vigneron, Irena Ilovayskaya, FARIDA A. NASYBULLINA, Samia Achir, Diego Ferone, Sebastian J.C.M.M. Neggers, Brigitte Delemer, Jean-Michel Petit, Christof Schöfl, Gérald Raverot, Bernard Goichot, Patrice Rodien, Bernard Corvilain, Thierry Christian Brue, Franck Schillo, Luaba Tshibanda, Dominique M. Maiter, Jean‐François Bonneville, Albert M. Beckers · 发表于：Endocrine Related Cancer · 年份：2016 · DOI：10.1530/erc-16-0356 · 被引用次数：113 · 研究领域：Pituitary Gland Disorders and Treatments、Growth Hormone and Insulin-like Growth Factors、Adrenal and Paraganglionic Tumors

GH-secreting pituitary adenomas can be hypo-, iso- or hyper-intense on T2-weighted MRI sequences. We conducted the current multicenter study in a large population of patients with acromegaly to analyze the relationship between T2-weighted signal intensity on diagnostic MRI and hormonal and tumoral responses to somatostatin analogs (SSA) as primary monotherapy. Acromegaly patients receiving primary SSA for at least 3 months were included in the study. Hormonal, clinical and general MRI assessments were performed and assessed centrally. We included 120 patients with acromegaly. At diagnosis, 84, 17 and 19 tumors were T2-hypo-, iso- and hyper-intense, respectively. SSA treatment duration, cumulative and mean monthly doses were similar in the three groups. Patients with T2-hypo-intense adenomas had median SSA-induced decreases in GH and IGF-1 of 88% and 59% respectively, which were significantly greater than the decreases observed in the T2-iso- and hyper-intense groups (P < 0.001). Tumor shrinkage on SSA was also significantly greater in the T2-hypo-intense group (38%) compared with the T2-iso- and hyper-intense groups (8% and 3%, respectively; P < 0.0001). The response to SSA correlated with the calculated T2 intensity: the lower the T2-weighted intensity, the greater the decrease in random GH (P < 0.0001, r = 0.22), IGF-1 (P < 0.0001, r = 0.14) and adenoma volume (P < 0.0001, r = 0.33). The T2-weighted signal intensity of GH-secreting adenomas at diagnosis correlates with horm...